CellaVision AB (publ)
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB (publ) (CLVSF) - Net Assets
Latest net assets as of December 2025: $887.58 Million USD
Based on the latest financial reports, CellaVision AB (publ) (CLVSF) has net assets worth $887.58 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.09 Billion) and total liabilities ($207.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $887.58 Million |
| % of Total Assets | 81.07% |
| Annual Growth Rate | 23.43% |
| 5-Year Change | 63.37% |
| 10-Year Change | 330.5% |
| Growth Volatility | 29.05 |
CellaVision AB (publ) - Net Assets Trend (2007–2025)
This chart illustrates how CellaVision AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CellaVision AB (publ) (2007–2025)
The table below shows the annual net assets of CellaVision AB (publ) from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $887.58 Million | +8.65% |
| 2024-12-31 | $816.89 Million | +14.03% |
| 2023-12-31 | $716.39 Million | +11.65% |
| 2022-12-31 | $641.63 Million | +18.10% |
| 2021-12-31 | $543.28 Million | +26.46% |
| 2020-12-31 | $429.62 Million | +23.32% |
| 2019-12-31 | $348.37 Million | +19.97% |
| 2018-12-31 | $290.38 Million | +20.56% |
| 2017-12-31 | $240.85 Million | +16.82% |
| 2016-12-31 | $206.18 Million | +12.35% |
| 2015-12-31 | $183.52 Million | +21.30% |
| 2014-12-31 | $151.30 Million | +14.17% |
| 2013-12-31 | $132.52 Million | +6.09% |
| 2012-12-31 | $124.91 Million | -0.92% |
| 2011-12-31 | $126.07 Million | +11.15% |
| 2010-12-31 | $113.42 Million | +51.64% |
| 2009-12-31 | $74.80 Million | +62.66% |
| 2008-12-31 | $45.98 Million | +129.10% |
| 2007-12-31 | $20.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CellaVision AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $887.58 Million | 100.00% |
| Total Equity | $887.58 Million | 100.00% |
CellaVision AB (publ) Competitors by Market Cap
The table below lists competitors of CellaVision AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enjoyor
SHE:300020
|
$380.16 Million |
|
Dingli Communications Corp Ltd
SHE:300050
|
$380.27 Million |
|
MEC Company Ltd.
PINK:MECGF
|
$380.40 Million |
|
Kangxin New Materials Co Ltd
SHG:600076
|
$380.51 Million |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
$380.07 Million |
|
Fine Organic Industries Limited
NSE:FINEORG
|
$379.90 Million |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
$379.85 Million |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
$379.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CellaVision AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 815,727,000 to 887,578,000, a change of 71,851,000 (8.8%).
- Net income of 153,078,000 contributed positively to equity growth.
- Dividend payments of 59,629,000 reduced retained earnings.
- Other comprehensive income decreased equity by 29,733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $153.08 Million | +17.25% |
| Dividends Paid | $59.63 Million | -6.72% |
| Other Comprehensive Income | $-29.73 Million | -3.35% |
| Other Changes | $8.13 Million | +0.92% |
| Total Change | $- | 8.81% |
Book Value vs Market Value Analysis
This analysis compares CellaVision AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 22.91x to 0.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.84 | $19.28 | x |
| 2008-12-31 | $1.93 | $19.28 | x |
| 2009-12-31 | $3.14 | $19.28 | x |
| 2010-12-31 | $4.76 | $19.28 | x |
| 2011-12-31 | $5.29 | $19.28 | x |
| 2012-12-31 | $5.24 | $19.28 | x |
| 2013-12-31 | $5.56 | $19.28 | x |
| 2014-12-31 | $6.34 | $19.28 | x |
| 2015-12-31 | $7.69 | $19.28 | x |
| 2016-12-31 | $8.64 | $19.28 | x |
| 2017-12-31 | $10.10 | $19.28 | x |
| 2018-12-31 | $12.17 | $19.28 | x |
| 2019-12-31 | $14.61 | $19.28 | x |
| 2020-12-31 | $18.01 | $19.28 | x |
| 2021-12-31 | $22.78 | $19.28 | x |
| 2022-12-31 | $26.90 | $19.28 | x |
| 2023-12-31 | $30.03 | $19.28 | x |
| 2024-12-31 | $34.20 | $19.28 | x |
| 2025-12-31 | $37.21 | $19.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CellaVision AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.25%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.17%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.23x
- Recent ROE (17.25%) is below the historical average (23.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.08% | 3.52% | 1.69x | 2.20x | $617.80K |
| 2008 | 54.48% | 24.94% | 1.04x | 2.10x | $20.46 Million |
| 2009 | 37.06% | 25.44% | 0.96x | 1.52x | $20.24 Million |
| 2010 | 33.81% | 29.13% | 0.81x | 1.43x | $27.01 Million |
| 2011 | 11.61% | 9.42% | 0.87x | 1.42x | $2.03 Million |
| 2012 | 5.16% | 3.81% | 0.95x | 1.43x | $-6.04 Million |
| 2013 | 14.29% | 10.53% | 0.95x | 1.42x | $5.68 Million |
| 2014 | 20.80% | 14.51% | 1.07x | 1.34x | $16.34 Million |
| 2015 | 28.78% | 22.07% | 1.09x | 1.20x | $34.47 Million |
| 2016 | 29.00% | 22.56% | 1.03x | 1.24x | $39.18 Million |
| 2017 | 28.95% | 22.54% | 1.03x | 1.25x | $45.64 Million |
| 2018 | 30.54% | 24.31% | 0.98x | 1.28x | $59.65 Million |
| 2019 | 28.47% | 21.48% | 0.72x | 1.84x | $64.33 Million |
| 2020 | 20.83% | 18.98% | 0.71x | 1.55x | $46.52 Million |
| 2021 | 23.07% | 22.16% | 0.69x | 1.52x | $71.01 Million |
| 2022 | 18.44% | 18.51% | 0.72x | 1.39x | $54.17 Million |
| 2023 | 18.19% | 19.24% | 0.73x | 1.30x | $58.67 Million |
| 2024 | 17.25% | 19.46% | 0.71x | 1.24x | $59.15 Million |
| 2025 | 17.25% | 20.17% | 0.69x | 1.23x | $64.32 Million |
Industry Comparison
This section compares CellaVision AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CellaVision AB (publ) (CLVSF) | $887.58 Million | 13.08% | 0.23x | $380.14 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |